These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 12891312)

  • 1. [Effect of drug therapy on frequency of adequate discharges of implanted cardioverter defibrillator].
    Tiroke A; Ganeeva ON
    Kardiologiia; 2003; 43(6):54-8. PubMed ID: 12891312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of appropriate cardioverter-defibrillator shocks in 1038 consecutive patients with implantable cardioverter-defibrillators.
    Kruger A; Aronow WS; Lai H; Desai H; Singla A; Frishman WH; Cohen M; Sorbera C
    Am J Ther; 2009; 16(4):323-5. PubMed ID: 19617719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators.
    Bollmann A; Husser D; Cannom DS
    Am J Cardiovasc Drugs; 2005; 5(6):371-8. PubMed ID: 16259525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Implantable cardioverter defibrillator does not eliminate need for antiarrhythmic drugs in secondary prevention of life threatening ventricular arrhythmias. Results of OPTIC trial].
    Iavelov IS
    Kardiologiia; 2006; 46(3):74-5. PubMed ID: 16710262
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
    Hohnloser SH; Dorian P; Roberts R; Gent M; Israel CW; Fain E; Champagne J; Connolly SJ
    Circulation; 2006 Jul; 114(2):104-9. PubMed ID: 16818810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter defibrillators.
    Ho AT; Pai SM; Timothy P; Pai RG
    Pacing Clin Electrophysiol; 2005 Jul; 28(7):647-53. PubMed ID: 16008799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Antiarrhythmic Medications in Medicare Part D Patients With an Implantable Cardioverter-Defibrillator and Ventricular Tachycardia.
    Pokorney SD; Mi X; Hammill BG; Allen LaPointe NM; Curtis LH; Al-Khatib SM
    Am J Cardiol; 2017 May; 119(9):1401-1406. PubMed ID: 28341360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antiarrhythmic therapy in patients with heart failure].
    Faber TS; Zehender M
    Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
    Connolly SJ; Dorian P; Roberts RS; Gent M; Bailin S; Fain ES; Thorpe K; Champagne J; Talajic M; Coutu B; Gronefeld GC; Hohnloser SH;
    JAMA; 2006 Jan; 295(2):165-71. PubMed ID: 16403928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.
    Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators
    N Engl J Med; 1997 Nov; 337(22):1576-83. PubMed ID: 9411221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of antiarrhythmic drugs: frequent implantable cardioverter-defibrillator shocks, risk of proarrhythmia, and new drug therapy.
    Droogan C; Patel C; Yan GX; Kowey PR
    Heart Fail Clin; 2011 Apr; 7(2):195-205, viii. PubMed ID: 21439498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions between implantable cardioverter-defibrillators and class III agents.
    Movsowitz C; Marchlinski FE
    Am J Cardiol; 1998 Aug; 82(4A):41I-48I. PubMed ID: 9737653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of patients with life-threatening sustained ventricular tachyarrhythmias--the role of guided antiarrhythmic drug therapy.
    Steinbeck G; Greene HL
    Prog Cardiovasc Dis; 1996; 38(6):419-28. PubMed ID: 8638023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sotalol in patients with implanted automatic defibrillators: effects on defibrillation and comparison with amiodarone.
    Dorian P; Newman D; Harris L; Downar E
    Can J Cardiol; 1994 Mar; 10(2):193-200. PubMed ID: 8143220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implantable defibrillators and/or amiodarone: alternatives or complementary therapies.
    Dorian P; Newman D; Greene M
    Int J Clin Pract; 1998 Sep; 52(6):425-8. PubMed ID: 9894382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of amiodarone in the era of the implantable cardioverter defibrillator.
    Dorian P; Mangat I
    J Cardiovasc Electrophysiol; 2003 Sep; 14(9 Suppl):S78-81. PubMed ID: 12950525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjunctive therapy for recurrent ventricular tachycardia in patients with implantable cardioverter defibrillators.
    Reiffel JA
    Curr Cardiol Rep; 2007 Sep; 9(5):381-6. PubMed ID: 17877933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of long-standing implantable cardioverter-defibrillator patients with and without appropriate therapy for ventricular arrhythmias: impact of a widening QRS.
    Dizon J; Chen K; Dizon S; Biviano A; Whang W; Ehlert F; Vazquez J; Nazif T; Garan H
    Europace; 2011 Jan; 13(1):77-81. PubMed ID: 21149513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlling cardiac arrhythmias: an overview with a historical perspective.
    Singh BN
    Am J Cardiol; 1997 Oct; 80(8A):4G-15G. PubMed ID: 9354407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Empiric antiarrhythmic drug therapy in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia: pragmatism or anachronism?
    Mitchell LB
    J Am Coll Cardiol; 2009 Aug; 54(7):616-7. PubMed ID: 19660691
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.